17412-38-3 Usage
Uses
Used in Pharmaceutical Industry:
6-METHYLIMIDAZO[1,2-B]PYRIDAZINE is used as a building block for the synthesis of various drug molecules due to its unique structure and properties. It plays a crucial role in the development of new pharmaceuticals with potential therapeutic applications.
Used in Antitumor Applications:
6-METHYLIMIDAZO[1,2-B]PYRIDAZINE is used as an antitumor agent, exhibiting potential in the treatment of various types of cancer. Its biological activities contribute to its effectiveness in targeting and inhibiting tumor growth.
Used in Antimicrobial Applications:
6-METHYLIMIDAZO[1,2-B]PYRIDAZINE is used as an antimicrobial agent, demonstrating potential in combating various types of microorganisms, including bacteria and fungi. Its ability to disrupt microbial processes makes it a valuable component in the development of new antimicrobial drugs.
Used in Chemical Reactions:
6-METHYLIMIDAZO[1,2-B]PYRIDAZINE is used as a solvent in chemical reactions, facilitating specific reaction pathways and improving the efficiency of certain processes. Its unique properties make it suitable for use in a variety of chemical applications.
Used in Organic Chemistry Research:
6-METHYLIMIDAZO[1,2-B]PYRIDAZINE is used as a research tool in organic chemistry, aiding scientists in understanding the structure, properties, and potential applications of 6-METHYLIMIDAZO[1,2-B]PYRIDAZINE. It serves as a valuable resource in the exploration of new chemical reactions and the development of novel bioactive compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 17412-38-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,4,1 and 2 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 17412-38:
(7*1)+(6*7)+(5*4)+(4*1)+(3*2)+(2*3)+(1*8)=93
93 % 10 = 3
So 17412-38-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H7N3/c1-6-2-3-7-8-4-5-10(7)9-6/h2-5H,1H3
17412-38-3Relevant academic research and scientific papers
GCN2 INHIBITORS AND USES THEREOF
-
Paragraph 00971; 00972, (2019/08/12)
The present invention provides compounds, compositions thereof, and methods of using the same.
Optimization of an imidazopyridazine series of inhibitors of plasmodium falciparum calcium-dependent protein kinase 1 (Pf CDPK1)
Chapman, Timothy M.,Osborne, Simon A.,Wallace, Claire,Birchall, Kristian,Bouloc, Nathalie,Jones, Hayley M.,Ansell, Keith H.,Taylor, Debra L.,Clough, Barbara,Green, Judith L.,Holder, Anthony A.
, p. 3570 - 3587 (2014/05/20)
A structure-guided design approach using a homology model of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) was used to improve the potency of a series of imidazopyridazine inhibitors as potential antimalarial agents. This resulted in high affinity compounds with PfCDPK1 enzyme IC 50 values less than 10 nM and in vitro P. falciparum antiparasite EC50 values down to 12 nM, although these compounds did not have suitable ADME properties to show in vivo efficacy in a mouse model. Structural modifications designed to address the ADME issues, in particular permeability, were initially accompanied by losses in antiparasite potency, but further optimization allowed a good balance in the compound profile to be achieved. Upon testing in vivo in a murine model of efficacy against malaria, high levels of compound exposure relative to their in vitro activities were achieved, and the modest efficacy that resulted raises questions about the level of effect that is achievable through the targeting of PfCDPK1.
